Cover Page

Cite item


This article deals with peculiarities of development and clinical course of heart failure (HF) in diabetic patients, influence of diabetic cardiopathy on HF formation., role of genetic predictors of diabetes mellitus (DM) and HF formation, also the importance of treatment response predictors, the significance of a more «personalized» exposure in order to optimize treatment. The role of stationary and dynamic genomics was analyzed,
especially molecular visualization that allows the earliest possible intervention. The article also includes examples of molecular visualization use in diagnosis of myocardial dysfunction, disease monitoring, and treatment efficacy assessment. Authors give an analysis of targeted treatment methods on the example of targeted delivery of medications to the target-organ (myocard). Discuss means of anti-ischemic myocardial protection, perspectives of metformin use in order to enhance efficacy of myocardial ischemic pre- and postconditioning mechanisms. Presented perspectives of study of molecular and genetic mechanisms involved in the pathogenesis of HF in diabetic patients, in particular, study of key biological features of stem cells, cell interactions, stem cell plasticity (in vitro direction of differentiation) and their paracrine function evaluation. Given information about identification of genes with partly altered expression due to chronic exposure of mesenchymal stem cells to the high concentration of glucose, and upon decreased ability of mesenchymal stem cells of proangiogenic factors with simultaneous increase of inflammatory markers production (IL8). In whole this article reviews modern state of HF in diabetic patients development mechanisms study with the use of molecular and genetic technologies, and of perspectives of development of this area.

About the authors

Е. V. Shlyakhto

Almazov Federal centre for heart, blood and endocrinology Ministry of Healthcare and Social development of Russia, St. Petersburg

Author for correspondence.
доктор медицинских наук, профессор, Заслуженный деятель науки РФ, ака- демик РАМН, директор ФГБУ «Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова» Минздравсоцразвития России Адрес: 197341, Санкт-Петербург, ул. Аккуратова, 2 Тел.: (812) 702-37-00; факс (812) 702-37-01 Russian Federation


  1. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail. Rev. 2000; 5 (2): 167–173.
  2. Ryd n L., Tsch pe D., D rr R. Diabetes and the heart — revisited. Herz. 2008; 33 (3): 169.
  3. Fein F.S. Diabetic cardiomyopathy. Diabetes Care. 1990; 13 (11): 1169–79.
  4. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation. 2007; 115 (25): 3213–23.
  5. Prokopenko I., McCarthy M.I., Lindgren C.M. Type 2 diabetes: new genes, new understanding. Trends Genet. 2008; 24 (12): 613–21.
  6. McCarthy M.I., Hattersley A.T. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes. 2008; 57 (11): 2889–98.
  7. Shlyakhto E., Sitnikova M., Krasnova O. et al. Polymorphism gene ACE in patient with systolic heart failure and it interaction with risk factors and 5-years survival. Article. Sixth International Congress of Cardiology for Internet, Argentine. 2009. TL063.
  8. Schroner Z., Javorsky M., Kozarova M. et al. Pharmacogenetics of oral antidiabetic treatment. Bratisl. Lek. Listy. 2011; 112 (8): 441–6.
  9. Galagudza M.M., Papayan G.V., Vlasov T.D. et al. Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya – Regional circulation and microcirculation. 2009; 8: 2 (30): 76–78.
  10. Shlyakhto E.V., Tsyrlin V.A., Petrishchev N.N. et al. Meditsinskii akademicheskii zhurnal = Medical academic journal. 2009; 9 (4): 113–120.
  11. Galagudza M.M., Korolev D.V., Sonin D.L. et al. Byulleten' eksperimental'noi biologii i meditsiny = Bulletin of experimental biology and medicine. 2011; 152 (7): 113–116.
  12. Galagudza M.M., Korolev D.V., Sonin D.L. et al. Rossiiskie nanotekhnologii = Russian nanotechnology. 2010; 5 (11–12): 92–97.
  13. Galagudza M.M., Korolev D.V., Sonin D.L. et al. Nanotekhnologii v biologii i meditsine = Nanotechnology in Biology and Medicine. 2010; 1: 132–138.
  14. Galagudza M.M., Korolev D.V., Sonin D.L. et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. International Journal of Nanomedicine. 2010; 5: 231–237.
  15. Shlyakhto E.V., Nifontov E.M., Galagudza M.M. Serdechnaya nedostatochnost' = Heart failure. 2008; 9 (1): 4–10.
  16. Shlyakhto E.V., Nifontov E.M., Galagudza M.M. Kreativnaya kardiologiya = Creative cardiology. 2007; 1–2: 75–102.
  17. Galagudza M.M., Nekrasova M.K., Syrenskii A.V. et al. Rossiiskii fiziologicheskii zhurnal im. I.M. Sechenova = Sechenov Russian physiological journal. 2006; 92 (3): 284–291.
  18. Kravchuk E., Grineva E., Bairamov A. et al. The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II. Exp. Diabetes Res. 2011; 907496. Epub. 2011 Jun 22.

Copyright (c) 2012 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies